Confidential

A new class of drugs to modulate

THE HUMAN MICROBIOME

Jonathan Freeman

CBO

Jefferies Healthcare Conference

NYC 06-07-2017

CONFIDENTIAL

Important Information1

The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question

and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by PureTech Health plc (the "Company"). The

information in the Presentation is not intended to form the basis of any contract. By attending (whether in person or by telephone) or reading the Presentation, you agree to the conditions set out below.

THIS DOCUMENT AND THE PRESENTATION IS NOT A PROSPECTUS. The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe

for, any shares or other securities of the Company, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any

contract whatsoever relating to any securities.

This document and the Presentation contain statements that are or may be forward-looking statements. These statements are based on our management’s current beliefs, expectations and

assumptions about future events, conditions and results, and on information currently available to us. This document and the Presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give

undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

All statements other than statements of historical facts included in this document may be forward-looking statements, including statements that relate to the Company's future prospects,

developments and strategies. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “think,” “may,” “could,” “will,” “would,” “should,” “continue,” “potential,” “likely,” “opportunity” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking

statements. Additionally, statements concerning future matters such as our expectations of business and market conditions, development and commercialization of new products, enhancements of existing products or technologies, and other statements regarding matters that are not historical are forward-looking statements. Such statements are based on currently available operating,

financial and competitive information and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to:

The Company’s business is subject to a number of risks and uncertainties. These risks are described in the Company’s 2016 Annual Report and Accounts which can found on the Company’s web

site at http://puretechhealth.com/investors-reports-presentations.php.

Given these risks, uncertainties and other factors, many of which are beyond our control, you should not place undue reliance on these forward-looking statements.

Each forward-looking statement speaks only as at the date of this document. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise

any forward-looking statements to reflect events or developments occurring after the date of this document, even if new information becomes available in the future.

The Presentation is confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by its recipients to any other person for any purpose, other than with the consent of the Company. The Presentation does not constitute or form part of an offer or invitation to issue or sell, or the solicitation of an offer to subscribe or purchase, any securities to any person.

By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (ii) you

have read and agree to comply with the contents of this notice.

1: Vedanta Biosciences is a subsidiary of PureTech Health

CONFIDENTIAL

Medicine meets Ecology

3

CONFIDENTIAL

What Makes Vedanta Unique?

Careful science, independently reproduced, peer reviewed

in seminal papers (Nature, Science, Cell)

World leading scientific founders in immunology/microbiome

Top Science in

Microbiome Field

Key IP for development of bacterial consortia drugs

Issued composition of matter claims covering key

highly abundant gut bacteria

Earliest priority dates among microbiome companies

Applying pharma rigor to rationally select defined drugs

based on consortia of live commensal bacteria

Safer, more scalable, reproducible than fecal transplants

Validated discovery & GMP manufacturing platform for

defined bacterial drugs

Sole focus on

Rationally-Defined

Live Bacterial Drugs

4

Foundational

Microbiome IP

CONFIDENTIAL 5

Pioneering Microbiome-Derived Immunotherapies Relevant to Immune-driven and Infectious Disease

CONFIDENTIAL

Co-Founders and Scientific AdvisorsMicrobiome and Immunology Pioneers

Discovered role of Toll–Like Receptors in

immunity

First to clone CD4 Co-Receptor, Pioneered

understanding of Th17 cellsDan Littman

Alexander Rudensky Pioneered under-standing of regulatory T cells

(Treg) & discovered role of Foxp3

Brett FinlayPioneer of host-microbe interactions &

mechanisms of infection

Kenya HondaPioneer of host-microbe interactions, discovered

role of microbiota in immunoregulation

6

Ruslan Medzhitov

Jeremiah Faith Leader in development of experimental and

computational tools to study the microbiota

CONFIDENTIAL

Rationally Defined Bacterial Consortia?Ecology-Level Interventions Designed with Pharmaceutical Rigor

7

Fecal Transplant Procedures

Defined Bacterial Consortia Drugs

Single Strains orSmall Molecules

Overly reductionistic,

fails at shifting ecosystem

Can shift ecosystem,

untargeted, variable procedure

Shifts ecosystem with

targeted immune responses

CONFIDENTIAL

Rationally Defined Bacterial ConsortiaEcology-Level Interventions Designed with Pharmaceutical Rigor

8

Single Strains

Imm

unolo

gic

al eff

ect

e.g

. Fo

xp3 +

CD

4

Single strains don’t reproducibly shift

microbiome, weak immune modulation

Rationally defined consortia capable of

shifting microbiome, robust immune response

CONFIDENTIAL

Rationally-Designed Bacterial Consortia Examples of Commensal Consortia Effective in Pre-clinical models

9

C. difficile Infection

Negative control

Positive control

Consortium

Sur

viva

l

Time

IL10-/- (colitis)

Sco

ring

Graft vs Host Disease

+LBP+LBP)

Sur

viva

l

Time

Negative control

Induced Food Allergy

+LBP

Sco

ring

Control

Consortium

Induction schedule

Consortium

CONFIDENTIAL 10

Foundational Intellectual Property Covering Large & Immunologically-Influential Microbiota Clusters

• DOMINANT PATENT POSITION TO OPERATE IN DEVELOPMENT OF BACTERIAL CONSORTIA DRUGS

• 12 ALLOWED PATENTS (US, EU, JP) BROADLY COVERING COMPOSITIONS OF MATTER, 2010 PRIORITY DATES

Clostridia Clusters IV and XIVa:

One of the Largest Clusters in the Microbiota

VE202

VE303

OthersFirmicutesBacteroidetes

Actinobacteria

Other

Total Microbiota Clostridia

Clusters IV and XIVa

CONFIDENTIAL

Platform for Sustainable Value CreationState-of-the-Art Capabilities and Assets in Microbiome Field

11

CONFIDENTIAL

Broad Translational Medicine-backed PipelineTargeting Patient Needs in Immune-driven and Infectious Disease

12

VE404 Food Allergy

VE606 MDROs and Graft-vs-Host Disease

VE808 Cancer Immunotherapy, Several Indications

DISCOVERY PRECLINICAL CLINICAL

VE303 C. difficile

VE202 Colitis & Crohn’s

GMP MANUF.

Aug 2016 — Analyzing gut microbiome patterns in melanoma, lung cancer, and bladder cancer patients associated with response, and developing microbiome-derived immunotherapies

Jan 2015 —licensing agreement for development of VE202 in IBD, with up-front and milestone payments of up to $339M plus royalties

Feb 2017 — Analyzing changes in the gut microbiome that may explain clinical response to oral immunotherapies in children with peanut allergies

Feb 2017 — generating clinical data from microbiome interventional studies in C. difficile patients

Feb 2017 — generating clinical data from microbiome interventional and observational studies in graft-versus-host disease

CONFIDENTIAL

Chris ViehbacherChairman of Board of Directors; Former CEO

and Member of the Board of Directors, Sanofi

Ben ShapiroFormer Exec VP of Research, Merck; led

research programs for 25 FDA approvals of

drugs & vaccines

John LaMattinaFormer President of Global R&D, Pfizer; led

approval of numerous new drugs, including:

Tarceva, Chantix, Zoloft, Selzentry, Lyrica

Board of Directors

Management Team

Dan CoutoSVP, Head of Manufacturing & Operations;

Former SVP Manufacturing & Operations

ContraFect, Merck

Jonathan FreemanChief Business Officer Former SVP, Head

of Strategy Development and Portfolio

Management, Merck KGaA

Deb WinslowVP, Program Management & Operations

Former VP Project Management & QA

GTC Biotherapeutics, Ra pharma

13

Bernat OlleChief Executive Officer, Co-Founder;

MIT TR35 Spain Innovator of the Year,

MIT PhD in bacterial fermentation & MBA

Bruce RobertsChief Scientific Officer

Former Head MS & Autoimmunity, Sanofi

Genzyme; 9 approvals, including aubagio

Leadership Team Extensive Industry Experience

David SteinbergCo-Founder, Director;

Executive VP, PureTech Health

Erik SpekHead of IP

Former Director of IP, Epizyme;

Wolf & Greenfield

CONFIDENTIAL

SummaryPioneering Microbiome-Derived Immunotherapies

Addressing Multiple Therapeutic Indications in

Immune & Infectious DiseaseBroad Pipeline

Leading Therapeutics Company Pioneering Rational

Drug Development in Microbiome FieldTransformative Science

Issued Product Claims Covering Key Bacteria,

Encompassing 30-50% of Gut Microbiota

Foundational

Microbiome IP

Discovery and GMP Manufacturing Platform for Well-

Defined Live Bio-Therapeutic Products

Platform for

Well-Defined Drugs

Multiple Seminal Publications in Top-Tier Journals &

pharma partnershipExternal Validation

14